Sagetis to participate in a consortium for developing pharmacological chaperones for the treatment of two rare metabolic diseases

December 21, 2012

Barcelona – December 2012 – Sagetis is pleased to announce that MINECO has granted funding to the CHAPERONES project (IPT-2012-0561-010000) – Development of pharmacological chaperones for the treatment of rare metabolic diseases. 

 

In the consortium, led by Minoryx Therapeutics, also participates the biotechnology company Oryzon, Sagetis and PaloBiofarma, as well as research groups from the University of Barcelona and the Autonomous University of Madrid. The consortium has received 2.3M € of financing from the Ministry of Economy and Competitiveness, INNPACTO 2012 program (IPT-2012-0561-010000).

 

About Sagetis Biotech

 

At Sagetis Biotech we are devoted to developing innovative drug delivery technologies to tackle challenging unmet medical needs. Based in Barcelona, Sagetis Biotech was founded in 2010 as a spin-off from GEMAT (Materials Engineering Group) at IQS.

 

The company's versatile, polymeric-based platforms are designed to tackle highly challenging areas, such as (i) delivery through difficult-to-cross barriers(e.g. blood-brain barrier, intestinal mucus gel layer, ocular); (ii) efficient transfection of genetic material, using both viral and non-viral vectors.

 

 

 

 

 

 

Share on Facebook
Share on Twitter
Please reload

Featured Posts

SAGETIS BIOTECH GRANTS EXCLUSIVE LICENSE OF ITS VIROSHIELD TECHNOLOGY TO ARATINGA.BIO TNP FOR RETROVIRAL AND PLASMID-BASED APPLICATIONS

March 29, 2019

1/4
Please reload

Recent Posts
Please reload

© 2018 - Sagetis Biotech | Via Augusta 394 –  08017 - Barcelona (SPAIN)

www.sagetis-biotech.com | Privacy Policy